Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C4971006: Maplirpacept + Glofitamab in Relapsed/Refractory DLBCL
2022-502822-41-00Phase 2Completed
- Sponsor
- Pfizer
- Start
- Apr 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of maplirpacept in diffuse large B-cell lymphoma (DLBCL), sponsored by Pfizer. Primary endpoints: Dose-limiting toxicities (DLTs) - Phase 1b and Overall response (OR) - Phase 2. Started Apr 2025; status: completed.
02
Drugs
maplirpacept
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2022-502822-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502822-41-00.